SkinBioTherapeutics (LON:SBTX) Reaches New 1-Year High – What’s Next?

SkinBioTherapeutics plc (LON:SBTXGet Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 23 ($0.30) and last traded at GBX 22.49 ($0.29), with a volume of 1883149 shares trading hands. The stock had previously closed at GBX 20.50 ($0.26).

SkinBioTherapeutics Price Performance

The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01. The company has a 50 day moving average price of GBX 18.29 and a 200 day moving average price of GBX 15.67. The firm has a market cap of £51.38 million, a PE ratio of -13.83 and a beta of 2.01.

About SkinBioTherapeutics

(Get Free Report)

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.

Further Reading

Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.